Concepedia

Gill Holdsworth

GH

16

Publications

570

Citations

14

H-Index

2004

Active since

Affiliations

UCB Pharma (United Kingdom)(Current)

University of Leicester

Amgen (United States)

University of Glasgow

Gill Holdsworth is an author at UCB Pharma (United Kingdom) specializing in medicine, cellular physiology, and cell signaling.

ORCID

Top concepts

Publications per year

2004–2022

16

Publications

16

Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors

Gill Holdsworth, Patrick M. Slocombe, Carl Doyle et al. · Journal of Biological Chemistry · 2012 · 95 citations · Full text

Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists

Gill Holdsworth, Kevin Greenslade, Joby K. Jose et al. · Bone · 2017 · 58 citations · Full text

A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise

Stephen Gadomski, Claire Fielding, Andrés García‐García et al. · Cell stem cell · 2022 · 53 citations · Full text

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

James R. Turk, Aimée M. Deaton, Jun Yin et al. · Regulatory Toxicology and Pharmacology · 2020 · 46 citations · Full text

, , +18

Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects

Yao Yao, Frederic Kauffmann, Shogo Maekawa et al. · Scientific Reports · 2020 · 43 citations · Full text

Rows per page

1–5 of 16